Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
暂无分享,去创建一个
S. Bae | J. Jun | Tae-Hwan Kim | Soo-Kyung Cho | D. Yoo | Y. Sung | Chan-Bum Choi | S. Won | Dam Kim
[1] S. Bae,et al. Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases. , 2013, Seminars in arthritis and rheumatism.
[2] V. Vullo,et al. Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents , 2012, Clinical Rheumatology.
[3] G. Baron,et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy , 2012, Annals of the rheumatic diseases.
[4] S. Bae,et al. Treatment Persistence with TNF Blocker in Korean Rheumatoid Arthritis Patients , 2011 .
[5] K. Powell,et al. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. , 2011, MMWR. Morbidity and mortality weekly report.
[6] J. Kremer,et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.
[7] T. McDonnell,et al. Comparison of interferon γ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis , 2009, Annals of the rheumatic diseases.
[8] W. Souza,et al. Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis , 2009, Rheumatology International.
[9] J. Greenberg,et al. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic , 2007, Annals of the rheumatic diseases.
[10] J. Singh,et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. , 2003, Arthritis and rheumatism.
[11] P. Geusens,et al. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors , 2003, Annals of the rheumatic diseases.
[12] F. Breedveld,et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. , 2003, Arthritis and rheumatism.
[13] S. Buskin,et al. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. , 1999, JAMA.
[14] T. Joint. Chemotherapy and management of tuberculosis in the United Kingdom : recommendations 1998 Joint Tuberculosis , 1998 .
[15] J. Kremer,et al. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. , 1996, The Journal of rheumatology.